Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF5112 in Healthy Adult Participants
NCT07232121Phase 1Recruiting
- Sponsor
- Dragonfly Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing DF5112 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Jan 2026; status: recruiting.
02
Drugs
DF5112
Beyond the preview
Go deeper on NCT07232121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232121.